SYMBICORT Drug Patent Profile

When do Symbicort patents expire, and what generic alternatives are available?

Symbicort is a drug marketed by Astrazeneca and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SYMBICORT is budesonide; formoterol fumarate. There are twenty-two drug master file entries for this compound. Additional details are available on the budesonide; formoterol fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symbicort

Annual sales in 2022 were $3.6bn, indicating a strong incentive for generic entry (peak sales were $5.7bn in 2019).

There have been fifteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMBICORT

US Patents:	0
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMBICORT

Paragraph IV (Patent) Challenges for SYMBICORT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYMBICORT	Metered Inhalation	budesonide; formoterol fumarate dihydrate	80 mcg/4.5 mcg per inhalation and 160 mcg/4.5 mcg per inhalation	021929	1	2018-06-26

US Patents and Regulatory Information for SYMBICORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-001	Jul 21, 2006	AB	RX	Yes	Yes
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes	9,415,009
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-002	Jul 21, 2006	AB	RX	Yes	Yes
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes	10,716,753		Y

International Patents for SYMBICORT

See the table below for patents covering SYMBICORT around the world.

Country	Patent Number	Title	Estimated Expiration
Iceland	3959
Germany	60326320
World Intellectual Property Organization (WIPO)	9925406
Taiwan	490308
Australia	728125
Hong Kong	1045812
Brazil	9814139

Supplementary Protection Certificates for SYMBICORT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0613371	2002C/022	Belgium		PRODUCT NAME: BUDESONID. MICRONIS. AND FORMOTEROL. FUMARAS DIHYDR., NATL REGISTRATION NO/DATE: 624 IS 234 F 0 20010129; FIRST REGISTRATION: SE 16047 20000825
0613371	CA 2002 00019	Denmark
0613371	SPC016/2002	Ireland		SPC016/2002: 20041105, EXPIRES: 20150824
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515

Symbicort: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

This report details the investment fundamentals and patent landscape for Symbicort (budesonide/formoterol fumarate dihydrate), a combination inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The analysis focuses on market positioning, competitive dynamics, patent expiry, and potential future revenue streams.

What is Symbicort's Current Market Position?

Symbicort, developed by AstraZeneca, is a widely prescribed inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination therapy. It is indicated for the maintenance treatment of asthma in patients aged 6 years and older and for the maintenance treatment of COPD [1]. The drug is administered via a metered-dose inhaler (MDI) or a dry powder inhaler (DPI).

Key market drivers for Symbicort include:

• Prevalence of Respiratory Diseases: Asthma affects an estimated 25 million Americans, and COPD is the third-leading cause of death in the U.S. [2]. This large patient population provides a substantial market for effective treatments.
• Combination Therapy Efficacy: The dual action of an ICS to reduce inflammation and a LABA to provide bronchodilation offers a significant therapeutic benefit for managing these chronic conditions, particularly for patients whose symptoms are not adequately controlled by ICS alone.
• Established Brand Recognition and Physician Trust: Symbicort has been available for over a decade, fostering strong physician familiarity and patient adherence.

As of the most recent reporting periods, Symbicort generated significant revenue for AstraZeneca. For example, in 2022, global sales of Symbicort were approximately $3.1 billion [3]. This demonstrates its sustained market share despite increasing competition.

What is the Competitive Landscape for Symbicort?

Symbicort operates within a competitive market for respiratory therapeutics, facing both branded and generic alternatives.

Key Competitors:

• Advair Diskus/Advair HFA (fluticasone propionate/salmeterol): Formerly a dominant player, Advair's market share has been impacted by the loss of patent exclusivity and the subsequent introduction of generics.
• Breo Ellipta (fluticasone furoate/vilanterol): Another ICS/LABA combination from GlaxoSmithKline (GSK), Breo Ellipta targets similar patient populations and has gained traction in the market.
• Dulera (mometasone furoate/formoterol fumarate dihydrate): A direct competitor to Symbicort, Dulera is also an ICS/LABA combination offering.
• Anoro Ellipta (umeclidinium/vilanterol): This is a long-acting muscarinic antagonist (LAMA) and LABA combination, primarily used for COPD, representing a different therapeutic class but competing for the same patient segment.
• Generic ICS/LABA Combinations: The availability of generic versions of established ICS/LABA products has increased price pressure across the market.

Competitive Dynamics:

The competitive landscape is characterized by:

• Switching Barriers: While cost is a factor, physician prescribing habits, patient experience with specific inhaler devices, and formulary placement influence brand loyalty and switching.
• Device Differentiation: The usability and delivery mechanism of inhaler devices are critical. AstraZeneca has invested in optimizing its Turbuhaler and metered-dose inhaler devices for Symbicort, which can be a differentiator.
• Therapeutic Guidelines: Evolving treatment guidelines from organizations such as the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) influence preferred treatment regimens and impact the market share of different drug classes and combinations. The trend towards single inhaler triple therapy (ICS, LABA, and LAMA) for some COPD patients presents a potential long-term challenge to dual-combination therapies.

What is Symbicort's Patent and Exclusivity Status?

The intellectual property (IP) protection surrounding Symbicort has been a significant factor in its commercial success. However, key patents have expired or are nearing expiry, opening the door for generic competition.

Key Patent Expiries and Litigation:

• Composition of Matter Patents: The primary patents covering the active pharmaceutical ingredients (APIs) for budesonide and formoterol fumarate dihydrate have long since expired.
• Formulation and Method of Use Patents: AstraZeneca has historically relied on a portfolio of patents covering specific formulations, manufacturing processes, and methods of use (e.g., for specific dosage strengths or treatment regimens).
• Generic Entry: Several generic versions of Symbicort have entered the U.S. market. For instance, in late 2019, Teva Pharmaceuticals announced the U.S. launch of its generic Symbicort [4]. Other generic manufacturers have followed.
• Litigation: AstraZeneca has engaged in extensive patent litigation to defend its IP and delay generic entry. These battles often revolve around secondary patents covering aspects such as inhaler device technology or specific polymorphic forms of the APIs. The success of these litigations can significantly impact the timeline for generic competition.

Impact on Revenue:

The loss of market exclusivity and the subsequent introduction of generics have a direct and substantial negative impact on the revenue generated by branded Symbicort. Generic competition typically leads to price erosion and a significant decrease in market share for the originator product.

What are the Financial Projections and Revenue Drivers?

AstraZeneca's revenue from Symbicort is projected to decline as generic competition intensifies. However, the drug's established position and large patient base will likely support some level of continued sales.

Revenue Trends:

• Historical Growth: Prior to generic entry, Symbicort experienced strong revenue growth driven by its efficacy, brand recognition, and the expansion of its indications.
• Post-Generic Erosion: Following generic launches, branded Symbicort sales have seen a substantial decline. For example, AstraZeneca reported that Symbicort sales in the U.S. have been significantly impacted by generic competition.
• International Markets: The timing and impact of generic entry can vary by geographical region, with some markets experiencing generic availability later than others.

Future Revenue Drivers:

• Continued Prescriptions: Despite generics, a segment of the market will likely continue to prescribe branded Symbicort due to physician preference, patient loyalty, or specific formulary restrictions.
• Device Innovation: While less common for mature products, any future improvements or new delivery devices for Symbicort could potentially extend its commercial life or create niche markets.
• COPD Market Growth: The growing prevalence of COPD globally could provide a persistent demand for effective treatments like Symbicort, even in the presence of generics.

Risks:

• Intensifying Generic Competition: The increasing number of generic Symbicort products will further drive down prices and market share.
• Newer Therapies: The development and adoption of novel respiratory therapies, including biologics for severe asthma and new combination inhalers (e.g., triple therapies), could reduce the overall market share for ICS/LABA combinations.
• Reimbursement Pressures: Healthcare payers are increasingly scrutinizing drug costs, which can lead to formulary restrictions favoring generics or lower-cost alternatives.

What are the Key Takeaways for Investors?

Symbicort represents a mature pharmaceutical product in the respiratory therapeutic area. Its investment profile is characterized by strong historical performance now transitioning into a period of significant revenue decline due to patent expiry and generic competition.

• Declining Revenue Trajectory: Investors should anticipate a continued downward trend in branded Symbicort sales due to widespread generic availability in major markets.
• Residual Market Value: While declining, the established patient base and physician trust will ensure some residual revenue generation from branded Symbicort for an extended period.
• Generic Opportunity: The patent expiries create opportunities for generic manufacturers to capture market share and generate revenue.
• Competitive Pressures: The broader respiratory market remains highly competitive, with ongoing innovation in ICS/LABA, LAMA/LABA, and biologic therapies impacting all players.

Frequently Asked Questions

1. When did generic Symbicort first become available in the U.S.? Generic Symbicort began entering the U.S. market in late 2019 and early 2020, following the resolution or expiry of key patents.

2. What is the primary mechanism of action for Symbicort? Symbicort combines budesonide, an inhaled corticosteroid that reduces airway inflammation, with formoterol fumarate dihydrate, a long-acting beta-agonist that relaxes airway muscles, providing bronchodilation.

3. Are there any remaining significant patent protections for branded Symbicort in major markets? The primary patents covering the composition of matter and core formulations have expired. While AstraZeneca may hold secondary patents related to specific delivery devices or manufacturing processes, these have generally not prevented the widespread introduction of generic versions in key markets like the U.S.

4. What is the projected long-term revenue outlook for branded Symbicort? The long-term revenue outlook for branded Symbicort is projected to be significantly lower than its peak, with sales primarily driven by a smaller segment of prescribers and patients.

5. How does the emergence of single-inhaler triple therapies impact Symbicort? Single-inhaler triple therapies (ICS/LABA/LAMA) are increasingly recommended for certain COPD patients and for severe asthma, potentially reducing the need for dual bronchodilator therapy like Symbicort in those specific patient groups.

Citations

[1] AstraZeneca. (n.d.). Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol. Retrieved from https://www.symbicort.com/

[2] Centers for Disease Control and Prevention. (2022, October 20). Asthma. Retrieved from https://www.cdc.gov/asthma/ Centers for Disease Control and Prevention. (2022, November 17). Chronic Obstructive Pulmonary Disease (COPD). Retrieved from https://www.cdc.gov/tobacco/campaign/lung-story-short/copd/index.htm

[3] AstraZeneca. (2023, February 8). AstraZeneca PLC Full Year and Fourth Quarter 2022 Results. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-plc-full-year-and-fourth-quarter-2022-results.html

[4] Teva Pharmaceuticals. (2019, November 18). Teva Announces U.S. Launch of Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 160/4.8 mcg [Press Release]. Retrieved from https://www.tevapharm.com/media-center/press-releases/2019/teva-announces-u.s.-launch-of-symbicort-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-160-4.8-mcg/